首页> 美国卫生研究院文献>Journal of Cancer >CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients
【2h】

CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients

机译:CDKN2基因删除作为不良预后预测因素参与成人B谱系急性淋巴细胞白血病患者的进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Deletion of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) is well known in many hematologic malignancies, but only few reports have investigated this deletion effect on clinical prognosis. This study performed analysis of the CDKN2 deletion in 215 adult B- lineage acute lymphoblastic leukemia (B-ALL) patients, and related cytogenetic prognostic factors (BCR/ABL; E2A/PBXl; TEL/AML1; Mixed Lineage Leukemia (MLL) rearrangement; MYC, Immunoglobulin heavy locus (IGH) translocation). The prevalence of CDKN2 deletions in all study populations was 28.4%. There is no difference between patients with CDKN2 deletion and wild-type patients in sex, age, white blood cells (WBC) count, BM blast percentage, extra infiltration and induction complete remission (CR) rate. Analysis in relapse patients revealed that the distribution of CDKN2 deletion is higher in relapse patients (44.6%) than all patients (28.4%, P=0.006). Deletion of CDKN2 was significantly associated with poor outcomes including decreased overall survival (OS) (P<0.001), lower disease free-survival (DFS) (P<0.001), and increased cumulative incidence of relapse (P=0.002); Also, CDKN2 deletion was strongly associated with IGH translocation (P=0.021); and had an adverse effect on patients with BCR-ABL fusion gene or with MLL rearrangement. Patients with CDKN2 gene deletion benefited from allogenic hematopoietic stem cell transplantation (Allo-HSCT). Deletion of CDKN2 gene was commonly observed through leukemia progression and was poor prognostic marker in long-term outcomes.
机译:细胞周期蛋白依赖性激酶抑制剂2A / B(CDKN2A / B)的删除在许多血液系统恶性肿瘤中是众所周知的,但是只有很少的报道研究了这种删除对临床预后的影响。这项研究分析了215名成人B谱系急性淋巴细胞白血病(B-ALL)患者的CDKN2缺失,以及相关的细胞遗传学预后因素(BCR / ABL; E2A / PBXl; TEL / AML1;混合谱系白血病(MLL)重排; MYC,免疫球蛋白重基因座(IGH)易位)。在所有研究人群中,CDKN2缺失的患病率为28.4%。缺失CDKN2的患者与野生型患者在性别,年龄,白细胞(WBC)计数,BM blast百分比,额外浸润和诱导完全缓解(CR)率方面没有差异。对复发患者的分析显示,CDKN2缺失的分布在复发患者中(44.6%)高于所有患者(28.4%,P = 0.006)。 CDKN2的缺失与不良预后显着相关,包括总生存期(OS)降低(P <0.001),无病生存期(DFS)降低(P <0.001)和累积复发率增加(P = 0.002);另外,CDKN2缺失与IGH易位密切相关(P = 0.021);并对BCR-ABL融合基因或MLL重排的患者产生不利影响。 CDKN2基因缺失的患者受益于同种异体造血干细胞移植(Allo-HSCT)。 CDKN2基因的缺失通常通过白血病的进展而观察到,并且在长期预后中预后不良。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号